[{"NetIncomeLossConverted_1_Q3_USD":-17705000.0,"NetIncomeLossConverted_3_Q3_USD":-109916000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_3_Q3_USD":-49420000.0,"CommonStockSharesOutstanding_0_Q3_shares":42213364.0,"StockholdersEquity_0_Q3_USD":701588000.0,"EarningsPerShareBasic_1_Q3_USD":-0.42,"EarningsPerShareBasic_3_Q3_USD":-2.82,"RevenuesConverted_1_Q3_USD":25000000.0,"RevenuesConverted_3_Q3_USD":25000000.0,"Assets_0_Q3_USD":724633000.0,"CommonStockSharesConverted_0_Q3_shares":42213364.0,"Ticker":"TPTX","CIK":"1595893","name":"TURNING POINT THERAPEUTICS, INC.","OfficialName":"Turning Point Therapeutics Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"1579986704.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201112"}]